Business
Genflow Biosciences PLC Announces Preliminary Interim Results From Dog Study
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...
About this update from Genflow Biosciences Plc
[{"type":"text","content":"THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.","length":415,"tagName":"p"},{"type":"text","content":"Genflow Biosciences Plc","length":23,"tagName":"p"},{"type":"text","content":"Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged Dogs","length":96,"tagName":"p"},{"type":"text","content":"LONDON, UK / ACCESS Newswire / February 12, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces positive preliminary interim results from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial evaluating its proprietary SIRT6 centenarian gene therapy in aged dogs.","length":449,"tagName":"p"},{"type":"text","content":"Trial overviewThe randomised, blinded study, conducted by an independent contract research organisation, enrolled 24 beagle dogs aged over 10 years who were allocated to four groups: two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 cohort, and a control group.","length":289,"tagName":"p"},{"type":"text","content":"The interim analysis reflects outcomes observed during the dosing period. Additional endpoints remain under assessment.","length":119,"tagName":"p"},{"type":"text","content":"Preliminary interim resultsAll treatment groups demonstrated superior survival compared to the control group during the dosing period. No adverse events were observed, and all treatment modalities exhibited a favourable safety and tolerability profile suitable for use in aged companion animals.","length":296,"tagName":"p"},{"type":"text","content":"Across treatment cohorts, improvements were observed in several functional and observable endpoints, including quality of life, muscle mass preservation, frailty index reduction, and coat quality, relative to control animals, which exhibited expected age-related decline.","length":271,"tagName"...